EU's CHMP Warns About Boceprevir In HIV, Aliskiren In Diabetes, But Clears Orlistat And Reinstates Trasylol
This article was originally published in The Pink Sheet Daily
The EU's scientific advisory panel, the CHMP, recommends prescribing information changes for drug/drug interactions with Merck's Victrelis and adverse events with Novartis' aliskiren, but clears obesity therapy orlistat of causing liver injury and reverses its 2007 negative opinion on Bayer's Trasylol.
You may also be interested in...
FDA warns that use of aliskiren-containing blood pressure drugs with ACE inhibitors or angiotensin receptor blockers may increase risk of kidney impairment, hypotension and hyperkalemia; Novartis to continue to sell four other aliskiren products.
IQWiG turned down both GSK/Valeant’s Trobalt and Novartis’ Rasilamlo for lack of evidence of added benefit, after manufacturers’ choice of comparator deviated from those selected by the G-BA.
Kalydeco is expected to be a game-changer in cystic fibrosis, but its current label is applicable to only 4% of the patient population. Vertex, however, has an ongoing plan to expand Kalydeco’s label as both a monotherapy and in combination with other experimental CF agents.